Close

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. SPY
2. TSLA
3. RDDT
4. TCS:IN
5. ALAB
6. MSFT
7. C
8. JPM
9. AAPL
10. GS


Go back to Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
(NASDAQ: ARQT) Delayed: 10.09 -0.11 (1.08%)
Previous Close $10.20    52 Week High $ 
Open $10.18    52 Week Low $ 
Day High $10.47    P/E N/A 
Day Low $9.95    EPS $ 
Volume 2,688,210       

(NASDAQ: ARQT) Delayed: 10.09 -0.11 (1.08%)
Previous Close $10.20    52 Week High $ 
Open $10.18    52 Week Low $ 
Day High $10.47    P/E N/A 
Day Low $9.95    EPS $ 
Volume 2,688,210